Phase II trial of zolpidem in patients with progressive supranuclear palsy

Trial Profile

Phase II trial of zolpidem in patients with progressive supranuclear palsy

Planning
Phase of Trial: Phase II/III

Latest Information Update: 19 Aug 2015

At a glance

  • Drugs Zolpidem (Primary)
  • Indications Progressive supranuclear palsy
  • Focus Therapeutic Use
  • Sponsors Sellas Life Sciences Group
  • Most Recent Events

    • 19 Aug 2015 Sellas expects to initiate this study in the first half of 2016 with completion anticipated by second half of 2017.
    • 03 Dec 2014 New trial record
    • 14 Oct 2014 SELLAS has signed an agreement with Pharmaceutical Product Development (PPD) to advance the clinical development of its drug and this trial is expected to be initiated in the fourth quarter of 2014, according to a media release.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top